Effects of norlaudanosolinecarboxylic acids on enzymes of catecholamine metabolism. 1980

C J Coscia, and W J Burke, and M P Galloway, and A H Kosloff, and J M Lasala, and J McFarlane, and J S Mitchell, and M M O'Toole, and B L Roth

Enzymes involved in catecholamine metabolism were assayed in the presence of a new class of naturally occurring tetrahydroisoquinoline alkaloids, the norlaudanosolinecarboxylic acids (NLCAs). NLCAs inhibited tyrosine hydroxylase noncompetitively with respect to its substrate, tyrosine and the cofactor, 6-methyltetrahydropterin (NLCA Kj = 4 x 10(-4) M; 3',4'-deoxynorlaudanosolinecarboxylic acid (DNLCA) Kj = 1.5 x 10(-4) M). Adrenal dopamine-beta-hydroxylase was also inhibited by NLCAs [3'O-methylnorlaudanosolinecarboxylic acid (MNLCA) Kj = 1.2 x 10(-4) M] and NLCA is a competitive inhibitor of norepinephrine methylation by hepatic catechol-O-methyltransferase (NLCA Kj = 5.6 x 10(-5) M). While a slight reduction of rat adrenal monoamine oxidase by MNLCA was also observed, NLCA did not affect the oxidation of tyrosine by D-amino acid oxidase. Kinetic patterns of tyrosine aminotransferase and aromatic amono acid decarboxylase from rat liver were not altered by addition of 1 to 10 x 10(-5) M NLCA or its 3'-O-methyl ether (MNLCA). In vivo studies of brain tyrosine metabolism in mouse neonates corroborated results on the in vitro effect of DNLCA on tyrosine hydroxylase. The potential of high-pressure liquid chromatography was demonstrated in both enzyme assays and radiometric studies of in vivo metabolism.

UI MeSH Term Description Entries
D007546 Isoquinolines A group of compounds with the heterocyclic ring structure of benzo(c)pyridine. The ring structure is characteristic of the group of opium alkaloids such as papaverine. (From Stedman, 25th ed)
D008297 Male Males
D008996 Monoamine Oxidase Inhibitors A chemically heterogeneous group of drugs that have in common the ability to block oxidative deamination of naturally occurring monoamines. (From Gilman, et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p414) MAO Inhibitor,MAO Inhibitors,Reversible Inhibitors of Monoamine Oxidase,Monoamine Oxidase Inhibitor,RIMA (Reversible Inhibitor of Monoamine Oxidase A),Reversible Inhibitor of Monoamine Oxidase,Inhibitor, MAO,Inhibitor, Monoamine Oxidase,Inhibitors, MAO,Inhibitors, Monoamine Oxidase
D010208 Papaverine An alkaloid found in opium but not closely related to the other opium alkaloids in its structure or pharmacological actions. It is a direct-acting smooth muscle relaxant used in the treatment of impotence and as a vasodilator, especially for cerebral vasodilation. The mechanism of its pharmacological actions is not clear, but it apparently can inhibit phosphodiesterases and it may have direct actions on calcium channels. Cerespan,Papaverine Hydrochloride,Pavabid,Pavatym,Hydrochloride, Papaverine
D002264 Carboxylic Acids Organic compounds containing the carboxy group (-COOH). This group of compounds includes amino acids and fatty acids. Carboxylic acids can be saturated, unsaturated, or aromatic. Carboxylic Acid,Acid, Carboxylic,Acids, Carboxylic
D002395 Catecholamines A general class of ortho-dihydroxyphenylalkylamines derived from TYROSINE. Catecholamine,Sympathin,Sympathins
D003067 Coenzymes Small molecules that are required for the catalytic function of ENZYMES. Many VITAMINS are coenzymes. Coenzyme,Enzyme Cofactor,Cofactors, Enzyme,Enzyme Cofactors,Cofactor, Enzyme
D003605 D-Amino-Acid Oxidase dextro-Amino Acid Oxidase,D-Amino Acid Dehydrogenase,Acid Dehydrogenase, D-Amino,Acid Oxidase, dextro-Amino,D Amino Acid Dehydrogenase,D Amino Acid Oxidase,Dehydrogenase, D-Amino Acid,Oxidase, D-Amino-Acid,Oxidase, dextro-Amino Acid,dextro Amino Acid Oxidase
D004299 Dopamine beta-Hydroxylase Dopamine beta-Monooxygenase,Dopamine beta Hydroxylase,Dopamine beta Monooxygenase,beta-Hydroxylase, Dopamine,beta-Monooxygenase, Dopamine
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme

Related Publications

C J Coscia, and W J Burke, and M P Galloway, and A H Kosloff, and J M Lasala, and J McFarlane, and J S Mitchell, and M M O'Toole, and B L Roth
January 1965, Postepy biochemii,
C J Coscia, and W J Burke, and M P Galloway, and A H Kosloff, and J M Lasala, and J McFarlane, and J S Mitchell, and M M O'Toole, and B L Roth
March 1985, The Journal of clinical endocrinology and metabolism,
C J Coscia, and W J Burke, and M P Galloway, and A H Kosloff, and J M Lasala, and J McFarlane, and J S Mitchell, and M M O'Toole, and B L Roth
September 1966, Japanese heart journal,
C J Coscia, and W J Burke, and M P Galloway, and A H Kosloff, and J M Lasala, and J McFarlane, and J S Mitchell, and M M O'Toole, and B L Roth
January 1971, Methods of biochemical analysis,
C J Coscia, and W J Burke, and M P Galloway, and A H Kosloff, and J M Lasala, and J McFarlane, and J S Mitchell, and M M O'Toole, and B L Roth
March 1980, Clinical science (London, England : 1979),
C J Coscia, and W J Burke, and M P Galloway, and A H Kosloff, and J M Lasala, and J McFarlane, and J S Mitchell, and M M O'Toole, and B L Roth
December 1974, Japanese circulation journal,
C J Coscia, and W J Burke, and M P Galloway, and A H Kosloff, and J M Lasala, and J McFarlane, and J S Mitchell, and M M O'Toole, and B L Roth
January 1967, Problemy endokrinologii,
C J Coscia, and W J Burke, and M P Galloway, and A H Kosloff, and J M Lasala, and J McFarlane, and J S Mitchell, and M M O'Toole, and B L Roth
January 1978, European journal of pharmacology,
C J Coscia, and W J Burke, and M P Galloway, and A H Kosloff, and J M Lasala, and J McFarlane, and J S Mitchell, and M M O'Toole, and B L Roth
October 2002, Annals of the New York Academy of Sciences,
C J Coscia, and W J Burke, and M P Galloway, and A H Kosloff, and J M Lasala, and J McFarlane, and J S Mitchell, and M M O'Toole, and B L Roth
January 1990, Neurochemistry international,
Copied contents to your clipboard!